Horizon Discovery Buys Sage
Horizon gains exclusive access to zinc finger nucleases (ZFNs) for in vivo–model generation, and certain exclusive and nonexclusive CRISPR in vivo–related IP in CRISPR, ZFN and recombinant adeno-associated virus. Formerly a part of Sigma-Aldrich, Sage Labs was sold last year to management and Telegraph Hill Partners (see IBO 3/31/13).
Cambridge, UK 9/29/14—Horizon Discovery, a provider of gene-editing technology and services, has agreed to acquire Sage Labs for $48 million in cash and stock. Sage is a supplier of advanced in vivo transgenic disease models for use in preclinical research. Sage generated nine-month revenues of $4.7 million. Horizon stated that the acquisition diversifies its product and service offerings into adjacent markets, increases cost consolidation and cross-selling opportunities, strengthens Horizon’s intellectual property (IP) portfolio and enhances its US business. “The consolidated offering significantly strengthens Horizon commercially, allowing us to offer product, service and R&D programs to customers engaged at every state of translational-genomics and personalized-medicine research from sequence to treatment,” stated Horizon CEO Dr. Darrin M. Disley. Dr. David Smoller, former CEO of Sage, was named chief business office at Horizon.
